A broader array of U.S. equities is now actively engaged in the ongoing market surge, with leadership extending beyond the realm of artificial intelligence.
The equal-weighted S&P 500 has ascended by 10.4% this year as of Tuesday’s close, contrasting with a 9.7% increase in the market capitalization-weighted index.
Highlights
- Analysts from Citigroup and Wells Fargo observe an expanding U.S. market rally that is venturing beyond AI frontrunners, buoyed by mitigating tensions with Iran.
- UBS strategist Gerry Fowler points to the S&P 500 healthcare sector, which has contracted over 1% this year, as increasingly appealing due to favorable earnings revisions and comparatively lower valuations.
- Amgen has appreciated by 6.3% year to date, while the iShares IGV ETF, down 13% YTD, rebounded by over 14% in the second quarter as software equities recover.
Expanding Rally Stimulates Interest in Healthcare and Software
As reported by CNBC, strategists increasingly perceive the stock market rally as transcending the AI sphere that has dominated since late 2022.
This transition prompts investors to seek out sectors and stocks poised to benefit from a catch-up trade as market participation broadens.
Citigroup strategist Scott Chronert asserts that easing tensions between the U.S. and Iran is fostering broader gains.
In correspondence with clients, he expressed optimism regarding the current negotiations, emphasizing that the trend of expansion has already been initiated.
Wells Fargo analysts concur, asserting that Wall Street is on the cusp of an “everything rally,” as cyclical stocks experience a resurgence.
This perspective bolsters the notion that investor interest is increasingly shifting towards areas outside the most prominent AI-associated firms.
Sector Positioning and Stock Selections
UBS strategist Gerry Fowler underscores healthcare as a notable area of opportunity, despite the S&P 500 healthcare sector’s more than 1% decline this year.
He indicates that the sector is gaining allure in the U.S., particularly as earnings forecasts turn favorable and valuations appear more attractive than those of ongoing AI capital spending beneficiaries.
Among specific stocks, Fowler identifies Amgen as a potential standout, having appreciated 6.3% thus far this year. Eli Lilly and Cardinal Health are also highlighted as probable beneficiaries of this shifting landscape.
Furthermore, Fowler notes that beleaguered growth sectors such as software are witnessing improved earnings revisions, which may underpin further ascents.
The iShares Expanded Tech-Software Sector ETF, IGV, remains down 13% year to date yet has surged over 14% in the second quarter.
A previous analysis highlighted Moderna’s stock movement, indicating how FDA briefing documents concerning the company’s mFlu influenza vaccine were perceived to diminish regulatory risks ahead of an advisory committee convening.
This assessment also suggested that investors may be beginning to reassess Moderna, looking beyond its COVID-19 vaccine legacy to its broader mRNA pipeline and upcoming Science Day updates that could further enhance its market potential.
This material may contain third-party opinions, and none of the data or information on this webpage constitutes investment advice as per our Disclaimer. While we adhere to strict Editorial Integrity, this post may reference products from our partners.
Source link: Tradersunion.com.
